🇺🇸 FDA

Intelligence · Clinical Pipeline

Metabolic & obesity · Phase III

Metabolic & obesity programs at Phase III — ClinicalTrials.gov pipeline intelligence.

Programs
227

Quick answer

Metabolic & obesity Phase III programs: NovaPharmaNews indexes 227 matching clinical development programs from ClinicalTrials.gov with sponsor, modality, and NCT cross-links.

Top sponsors

Page 4 of 5

  1. RO7795068, RO7795068, RO7795068, RO7795068, RO7795068, RO7795068 Placebo, RO7795068

    Hoffmann-La Roche

    Obesity or Overweight Without Type 2 Diabetes

    phase 3 small molecule active

    1 trial

  2. Resmetirom

    Madrigal Pharmaceuticals EU Limited

    NASH

    phase 3 small molecule active

    1 trial

  3. Retatrutide, Tirzepatide, Retatrutide, Tirzepatide, Tirzepatide, Tirzepatide, Retatrutide, Retatrutide, Retatrutide, Tirzepatide, Tirzepatide

    Eli Lilly Co.

    Obesity

    phase 3 small molecule active

    1 trial

  4. Rimonabant

    Sanofi Pasteur

    Obesity

    phase 3 small molecule terminated

    1 trial

  5. Rybelsus 7 mg tablets, Placebo (semaglutide) tablet, Rybelsus 3 mg tablets, Rybelsus 14 mg tablets

    NovoThirteen

    Type 2 diabetes

    phase 3 small molecule active

    1 trial

  6. Ryzodeg 100 units/mL FlexTouch solution for injection in pre-filled pen, IcoSema 700 U/mL + 2 mg/mL PDS290

    NovoThirteen

    Type 2 diabetes

    phase 3 small molecule active

    1 trial

  7. SYR-472

    Takeda

    Type 2 Diabetes Mellitus

    phase 3 small molecule completed

    1 trial

  8. SYR-472

    Takeda

    Diabetes Mellitus

    phase 3 small molecule completed

    5 trials

  9. Saxagliptin

    AstraZeneca

    Diabetes

    phase 3 small molecule completed

    1 trial

  10. Semaglutide B 1.34 mg/mL PDS290 3.0 mL, Wegovy 2.4 mg solution for injection in pre-filled pen, Pre-filled syringe (glass) in a pre-filled pen: Semaglutide placebo Ia DV3396 pen-injector, 0.5 mL Semaglutide placebo Ib DV3396 pen-injector, 0.75 mL, Semaglutide B 0.68 mg/mL PDS290 1.5 mL, Semaglutide D 1.0 mg/mL DV3396, Semaglutide D 2.0 mg/mL DV3396, Wegovy 0.25 mg solution for injection in pre-filled pen, Wegovy 2.4 mg FlexTouch solution for injection in pre-filled pen, Semaglutide B 3.2 mg/mL PDS290 3.0 mL

    NovoThirteen

    Non-alcoholic steatohepatitis (NASH)

    phase 3 small molecule active

    1 trial

  11. Setmelanotide

    Rhythm Pharmaceuticals Netherlands B.V.

    Obesity Associated With Defects in Leptin-melanocortin Pathway

    phase 3 small molecule active

    2 trials

  12. Setmelanotide

    Rhythm Pharmaceuticals Netherlands B.V.

    Obesity

    phase 3 small molecule active

    1 trial

  13. Setmelanotide

    Rhythm Pharmaceuticals Netherlands B.V.

    Leptin Receptor Deficiency Obesity

    phase 3 small molecule completed

    1 trial

  14. Setmelanotide

    Rhythm Pharmaceuticals Netherlands B.V.

    Hypothalamic Obesity

    phase 3 small molecule active

    3 trials

  15. Setmelanotide

    Rhythm Pharmaceuticals Netherlands B.V.

    Pro-opiomelanocortin (POMC) Deficiency Obesity

    phase 3 small molecule completed

    1 trial

  16. Sotagliflozin

    LEXICON PHARMACEUTICALS, INC.

    Type 2 Diabetes Mellitus

    phase 3 small molecule terminated

    3 trials

  17. Sotagliflozin

    LEXICON PHARMACEUTICALS, INC.

    Diabetic Nephropathies

    phase 3 small molecule active

    1 trial

  18. Sotagliflozin

    LEXICON PHARMACEUTICALS, INC.

    Type 1 Diabetes Mellitus

    phase 3 small molecule completed

    3 trials

  19. Sotagliflozin

    LEXICON PHARMACEUTICALS, INC.

    Type 1 Diabetes Mellitus (T1DM)

    phase 3 small molecule completed

    1 trial

  20. Sotagliflozin (SAR439954)

    LEXICON PHARMACEUTICALS, INC.

    Type 2 Diabetes Mellitus

    phase 3 small molecule completed

    4 trials

  21. Sotagliflozin Low Dose

    LEXICON PHARMACEUTICALS, INC.

    Type 1 Diabetes (T1D)

    phase 3 small molecule active

    1 trial

  22. Suspension of autologous mononuclear cells separated from bone marrow aspirate

    The George Institute

    diabetic foot syndrome, lower limb ischemia

    phase 3 small molecule active

    1 trial

  23. Suzetrigine

    Vertex Pharmaceuticals (Australia) Pty.

    Diabetic Peripheral Neuropathic Pain

    phase 3 small molecule active

    3 trials

  24. TAK-559

    Takeda

    Diabetes Mellitus

    phase 3 small molecule terminated

    3 trials

  25. TAK-559 and glyburide

    Takeda

    Diabetes Mellitus

    phase 3 small molecule terminated

    1 trial

  26. TAK-559 and insulin

    Takeda

    Diabetes Mellitus

    phase 3 small molecule terminated

    1 trial

  27. TAK-559 and metformin

    Takeda

    Diabetes Mellitus

    phase 3 small molecule terminated

    1 trial

  28. TAK-875

    Takeda

    Diabetic Patients

    phase 3 small molecule completed

    1 trial

  29. TAK-875

    Takeda

    Type 2 Diabetes

    phase 3 small molecule terminated

    1 trial

  30. TAK-875

    Takeda

    Type 2 Diabetes Mellitus

    phase 3 small molecule terminated

    1 trial

  31. TAK-875

    Takeda

    Diabetes Mellitus

    phase 3 small molecule completed

    3 trials

  32. TAK-875

    Takeda

    Diabetes Mellitus, Type 2

    phase 3 small molecule terminated

    4 trials

  33. TIRZEPATIDE, TIRZEPATIDE, Retatrutide, Retatrutide, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, Retatrutide, Retatrutide, TIRZEPATIDE, Placebo to match LY, Retatrutide, Placebo to match LY

    Eli Lilly Co.

    Metabolic Dysfunction-Associated Steatotic Liver Disease

    phase 3 small molecule active

    1 trial

  34. TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, Placebo to match LY3298176, TIRZEPATIDE, TIRZEPATIDE

    Eli Lilly Co.

    Obesity, Overweight

    phase 3 small molecule active

    1 trial

  35. Tang-min Lin pill

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Type 2 Diabetes

    phase 3 small molecule active

    1 trial

  36. Teplizumab

    Sanofi Pasteur

    Type 1 Diabetes Mellitus

    phase 3 small molecule active

    1 trial

  37. Teplizumab, Matched placebo for test product

    Sanofi-aventis Healthcare Pty Ltd

    Nutritional and metabolic diseases

    phase 3 small molecule active

    1 trial

  38. Tesaglitazar

    AstraZeneca

    Type 2 Diabetes

    phase 3 small molecule terminated

    1 trial

  39. Tesaglitazar 0.5 or 1 mg

    AstraZeneca

    Type 2 Diabetes

    phase 3 small molecule terminated

    1 trial

  40. Tirzepatide

    Eli Lilly and Company

    Metabolic Dysfunction-Associated Steatotic Liver Disease

    phase 3 small molecule active

    1 trial

  41. Tirzepatide, Tirzepatide, Tirzepatide, Tirzepatide, Mirikizumab, Mirikizumab, to match Tirzepatide, Tirzepatide, Mirikizumab, Tirzepatide

    Eli Lilly Co.

    Obesity or Overweight, Crohn’s Disease

    phase 3 small molecule active

    1 trial

  42. Tirzepatide, Tirzepatide, Tirzepatide, Tirzepatide, Tirzepatide, Tirzepatide, Placebo to match LY3298176 injection

    Eli Lilly Co.

    Obesity

    phase 3 small molecule active

    1 trial

  43. Tradipitant

    Lacuna Pharma Pty Ltd

    Idiopathic or diabetic gastroparesis with moderate to severe nausea.

    phase 3 small molecule active

    1 trial

  44. Trelagliptin 25 mg

    Takeda

    Type 2 Diabetes Mellitus

    phase 3 small molecule completed

    1 trial

  45. Trichosanthes root

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Diabetes Mellitus

    phase 3 small molecule active

    1 trial

  46. Trulicity 0.75 mg solution for injection in pre-filled pen

    The George Institute

    Metabolic syndrome in patients on the waiting list for kidney transplantation, Metabolic syndrome in patients on the waiting list for kidney transplantation

    phase 3 small molecule active

    1 trial

  47. Trulicity 0.75 mg solution for injection in pre-filled pen

    The George Institute

    Preventive treatment of post-kidney transplant diabetes

    phase 3 small molecule active

    1 trial

  48. UDCA

    The First People's Hospital of Lianyungang

    Diabetes Mellitus

    phase 3 small molecule active

    1 trial

Frequently asked questions

How many metabolic & obesity Phase III programs exist?

227 programs match both the therapeutic area and stage filters in our published index.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.